Longeveron Inc (LGVN)

$1.04

Market is closed - opens 7 PM, 05 Jun 2024

Insights on Longeveron Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 63.0K → 548.0K (in $), with an average increase of 88.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.02M → -4.05M (in $), with an average increase of 48.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 168.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 333.6%

Performance

  • $1.02
    $1.07
    $1.04
    downward going graph

    1.88%

    Downside

    Day's Volatility :4.64%

    Upside

    2.8%

    downward going graph
  • $1.02
    $40.00
    $1.04
    downward going graph

    1.92%

    Downside

    52 Weeks Volatility :97.45%

    Upside

    97.4%

    downward going graph

Returns

PeriodLongeveron IncIndex (Russel 2000)
3 Months
-79.65%
0.0%
6 Months
-94.9%
0.0%
1 Year
-96.97%
0.0%
3 Years
-98.46%
-22.6%

Highlights

Market Capitalization
7.0M
Book Value
$2.69
Earnings Per Share (EPS)
-9.6
Wall Street Target Price
14.05
Profit Margin
0.0%
Operating Margin TTM
-8598.41%
Return On Assets TTM
-66.49%
Return On Equity TTM
-157.19%
Revenue TTM
709.0K
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
-47.9%
Gross Profit TTM
497.0K
EBITDA
-20.1M
Diluted Eps TTM
-9.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.7
EPS Estimate Next Year
-3.94
EPS Estimate Current Quarter
-2.0
EPS Estimate Next Quarter
-1.8

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Longeveron Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1250.96%

Current $1.04
Target $14.05

Company Financials

FY18Y/Y Change
Revenue
2.1M
-
Net Income
-6.3M
-
Net Profit Margin
-296.84%
-
FY19Y/Y Change
Revenue
5.6M
↑ 164.17%
Net Income
-3.0M
↓ 52.73%
Net Profit Margin
-53.12%
↑ 243.72%
FY20Y/Y Change
Revenue
5.6M
↓ 0.18%
Net Income
-3.8M
↑ 26.56%
Net Profit Margin
-67.35%
↓ 14.23%
FY21Y/Y Change
Revenue
1.3M
↓ 76.8%
Net Income
-17.2M
↑ 352.73%
Net Profit Margin
-1.3K%
↓ 1246.89%
FY22Y/Y Change
Revenue
1.2M
↓ 6.43%
Net Income
-19.6M
↑ 14.35%
Net Profit Margin
-1.6K%
↓ 291.9%
FY23Y/Y Change
Revenue
709.0K
↓ 41.98%
Net Income
-21.4M
↑ 9.1%
Net Profit Margin
-3.0K%
↓ 1414.03%
Q4 FY22Q/Q Change
Revenue
121.0K
↓ 54.34%
Net Income
-3.8M
↓ 28.84%
Net Profit Margin
-3.1K%
↓ 1116.98%
Q1 FY23Q/Q Change
Revenue
279.0K
↑ 130.58%
Net Income
-4.6M
↑ 21.37%
Net Profit Margin
-1.6K%
↑ 1476.5%
Q2 FY23Q/Q Change
Revenue
217.0K
↓ 22.22%
Net Income
-5.6M
↑ 23.02%
Net Profit Margin
-2.6K%
↓ 954.53%
Q3 FY23Q/Q Change
Revenue
150.0K
↓ 30.88%
Net Income
-5.9M
↑ 4.83%
Net Profit Margin
-3.9K%
↓ 1340.61%
Q4 FY23Q/Q Change
Revenue
63.0K
↓ 58.0%
Net Income
-6.0M
↑ 2.1%
Net Profit Margin
-9.6K%
↓ 5632.25%
Q1 FY24Q/Q Change
Revenue
548.0K
↑ 769.84%
Net Income
-4.1M
↓ 32.68%
Net Profit Margin
-740.51%
↑ 8827.74%
FY18Y/Y Change
Total Assets
10.5M
-
Total Liabilities
3.7M
-
FY19Y/Y Change
Total Assets
10.6M
↑ 0.6%
Total Liabilities
6.1M
↑ 65.6%
FY20Y/Y Change
Total Assets
9.2M
↓ 12.7%
Total Liabilities
7.3M
↑ 18.63%
FY21Y/Y Change
Total Assets
42.8M
↑ 362.83%
Total Liabilities
5.3M
↓ 27.05%
FY22Y/Y Change
Total Assets
27.4M
↓ 35.9%
Total Liabilities
6.9M
↑ 30.06%
FY23Y/Y Change
Total Assets
12.2M
↓ 55.58%
Total Liabilities
5.3M
↓ 22.76%
Q4 FY22Q/Q Change
Total Assets
27.4M
↓ 10.17%
Total Liabilities
6.9M
↑ 17.12%
Q1 FY23Q/Q Change
Total Assets
21.8M
↓ 20.45%
Total Liabilities
5.5M
↓ 20.55%
Q2 FY23Q/Q Change
Total Assets
17.1M
↓ 21.62%
Total Liabilities
5.8M
↑ 6.19%
Q3 FY23Q/Q Change
Total Assets
11.6M
↓ 31.99%
Total Liabilities
5.0M
↓ 14.36%
Q4 FY23Q/Q Change
Total Assets
12.2M
↑ 4.76%
Total Liabilities
5.3M
↑ 6.89%
Q1 FY24Q/Q Change
Total Assets
9.7M
↓ 20.37%
Total Liabilities
6.7M
↑ 24.71%
FY18Y/Y Change
Operating Cash Flow
-5.2M
-
Investing Cash Flow
-211.7K
-
Financing Cash Flow
1.4M
-
FY19Y/Y Change
Operating Cash Flow
-2.4M
↓ 53.83%
Investing Cash Flow
-125.0K
↓ 40.93%
Financing Cash Flow
350.0K
↓ 74.17%
FY20Y/Y Change
Operating Cash Flow
-2.4M
↓ 1.13%
Investing Cash Flow
-261.5K
↑ 109.12%
Financing Cash Flow
1.6M
↑ 350.09%
FY21Y/Y Change
Operating Cash Flow
-9.6M
↑ 307.63%
Investing Cash Flow
-10.7M
↑ 3990.25%
Financing Cash Flow
45.2M
↑ 2767.59%
FY22Y/Y Change
Operating Cash Flow
-14.0M
↑ 44.97%
Investing Cash Flow
-677.0K
↓ 93.67%
Financing Cash Flow
-509.0K
↓ 101.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.3M
↓ 45.49%
Investing Cash Flow
-570.0K
↓ 76.14%
Financing Cash Flow
-193.0K
↑ 614.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.8M
↑ 153.38%
Investing Cash Flow
346.0K
↓ 160.7%
Financing Cash Flow
-17.0K
↓ 91.19%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 21.32%
Investing Cash Flow
2.5M
↑ 608.09%
Financing Cash Flow
-86.0K
↑ 405.88%

Technicals Summary

Sell

Neutral

Buy

Longeveron Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Longeveron Inc
Longeveron Inc
-38.1%
-94.9%
-96.97%
-98.46%
-98.6%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.54%
31.88%
92.14%
229.83%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
36.12%
71.83%
234.04%
457.53%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
32.76%
40.6%
124.79%
171.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Longeveron Inc
Longeveron Inc
NA
NA
NA
-4.7
-1.57
-0.66
NA
2.69
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Longeveron Inc
Longeveron Inc
Buy
$7.0M
-98.6%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
229.83%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
457.53%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
171.36%
29.59
39.46%

Institutional Holdings

  • Vanguard Group Inc

    0.38%

  • BlackRock Inc

    0.18%

  • Creative Planning Inc

    0.17%

  • Tower Research Capital LLC

    0.01%

  • Wells Fargo & Co

    0.01%

Company Information

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Organization
Longeveron Inc
Employees
23
CEO
Dr. Joshua Michael Hare FACC, M.D.
Industry
Miscellaneous

Discover More

FAQs